Infectious complications of tumor necrosis factor-alpha antagonists (Q36154725)

12 August 2017

1 reference

title

Infectious complications of tumor necrosis factor-alpha antagonists (English)

1 reference

12 August 2017

Mohanad Bakleh

1

1 reference

12 August 2017

Imad Tleyjeh

2

1 reference

12 August 2017

Eric L Matteson

3

1 reference

12 August 2017

Douglas R Osmon

4

1 reference

12 August 2017

Elie F Berbari

5

1 reference

12 August 2017

1 June 2005

1 reference

International Journal of Dermatology

12 August 2017

1 reference

12 August 2017

44

1 reference

12 August 2017

443-448

1 reference

12 August 2017

6

1 reference

Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression.

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

A randomized trial of etanercept as monotherapy for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Exercise capacity and mortality among men referred for exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Tuberculous tonsillitis in a patient receiving etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Experience with etanercept in an academic medical center: are infection rates increased?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Does administration of infliximab increase susceptibility to listeriosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Shingles following infliximab infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Disseminated Sporotrichosis Associated with Treatment with Immunosuppressants and Tumor Necrosis Factor–α Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2004.02571.X

10.1111/J.1365-4632.2004.02571.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference